Objectives In this study, a meta-analysis of observational studies was performed to compare the rate of recurrent neurological events (RNE) between transcatheter closure and medical management of patients with cryptogenic stroke/transient ischemic attack (TIA) and concomitant patent foramen ovale (PFO).
Epidemiological studies have found a prevalence of 44% to 66% of patent foramen ovale (PFO) in patients with cryptogenic stroke as compared with 27% in autopsy series of all-cause deaths (1) . The higher prevalence of PFO in patients with cryptogenic stroke suggests that at least in some patients with cryptogenic stroke, the cause of stroke might be paradoxical thromboembolism (PTE). However, it is important to realize that in many or possibly most patients with cryptogenic stroke and PFO, PTE might not be the cause of stroke. Percutaneous closure has been available for over 10 years with very little hard evidence to guide patient and device selection. Investigators have used their own clinical judgment to decide when and how to percutaneously close PFO. There is 1 multicenter randomized controlled trial (CLOSURE 1 [Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent
Foramen Ovale]) recently reported, and several trials are ongoing but with slow recruitment (2) . Although several single-center experiences indicated reduction in recurrent neurological events (RNE) after PFO closure, the CLOSURE 1 trial failed to demonstrate any significant difference in RNE with PFO closure compared with medical management with antiplatelet or anticoagulation therapy. Although the strength of a randomized trial is to minimize unmeasured biases, entry bias introduced by preferences of investigators and patients-especially when the same therapy is available outside the clinical trial-can play an important role in the adequacy of final study population. This is of particular relevance in this population where the chance of PFO being an innocent bystander is high. Single-center studies have even larger limitations, including small numbers of patients, reporting bias, and lack of an adequate control population, to name a few. However, they provide a unique insight to our understanding when a relatively rare clinical problem is investigated, and "clinical judgment" is exerted to select the treatment approach. Therefore, we performed a comprehensive meta-analysis of the available observational studies to evaluate the risk of RNE after transcatheter closure and medical therapy in patients with cryptogenic stroke/ transient ischemic attack (TIA) due to presumed paradoxical thromboembolism. We specifically focused on patient selection (PFO morphology and age) and complication rates to better understand the nonrandomized data. Due to scarcity of comparative published data, our metaanalysis does not primarily focus on the comparison of the 2 strategies, because it would be fraught with statistical biases arising from differences in methodology of different studies.
Methods
Search strategy. We queried Medline, EMBASE, and Cochrane databases for eligible studies with the terms "patent foramen ovale," "PFO," "atrial septal aneurysm," "ASA transcatheter closure," "heart septal defects (atrial)," "interatrial shunt," "recurrent thromboembolism," "recurrent stroke," and "recurrent TIA." We also evaluated studies reporting the efficacy of transcatheter PFO closure for indications other than stroke/TIA to derive comprehensive pooled estimates for device-related complications and postprocedure residual shunting. Study characteristics. We considered all observational studies, including prospective or retrospective cohort studies, case series, and comparative studies. Case series reporting outcomes after transcatheter closure with at least 100 patients were included. Comparative studies comparing transcatheter closure and medical therapy or case series reporting outcomes after medical management were included, regardless of the sample size. Studies reporting recurrent stroke or TIA after transcatheter PFO closure or medical management of presumed PTE through PFO were included for analysis. We excluded studies that reported composite outcomes for atrial septal defects along with PFO, unless it was possible to clearly determine the outcomes of PFO closure. In cases of research groups reporting cumulative results in multiple publications, caution was exercised in data extraction, and only studies with the largest sample size and follow-up period for each outcome were included. Outcome measures. Primary outcome was defined as recurrent stroke or TIA in the follow-up period. We analyzed the secondary outcomes of procedural failures, device-related complications, and residual shunting post-procedure. We conducted several subgroup analyses to best define the device and patient characteristics that might govern the occurrence of RNE in follow-up period. These included comparison of RNE among old versus young, PFO alone versus PFO with concomitant atrial septal aneurysm (ASA), antiplatelet versus anticoagulant therapies, and the effect of thrombophilia. Meta-analysis. Meta-analysis was carried out with the "metan" function in Stata (version 10.0, StataCorp, College Station, Texas). Fixed effects modeling was primarily used to conduct outcomes meta-analysis from included studies. Random effects modeling was used in case of significant statistical heterogeneity (I 2 Ͼ50% with p Ͻ 0.05). Publication biases were assessed separately for the transcatheter closure and the medical therapy arms, with the Abbreviations and Acronyms funnel plot method as well as Egger regression asymmetry testing (3) . In case of significant publication bias, we adjusted the pooled effect estimate with the Duval and Tweedie nonparametric "trim and fill" method of incorporating the estimates theoretically from the missing studies (4) .
Due to a relatively small number of RNE in each study, the data were assumed to follow a Poisson distribution. For each study, a 95% confidence interval (CI) estimate for RNE was computed with Poisson tables. Pooled incidence rates for the transcatheter closure arm or the medical therapy arm were calculated with the respective single-arm studies and by splitting the 2 arms of the comparative studies and including them in the respective groups. The pooled incidence rates for the RNE and composite complication rates were expressed as events/100 person-years (PY), whereas individual complication rates were more appropriately expressed as event/100 patients followed. The comparative estimates were derived only from the studies, which reported direct comparison of the transcatheter closure and medical therapy. Odds ratios, relative risk (RR), and/or risk differences (RD) were used to report pooled estimates for various comparisons. Meta-regression analysis was conducted to determine the difference in RNE rates between the 2 strategies after adjusting for age, sex, and presence of ASA. The meta-analysis has been reported in accordance with the Metaanalysis of Observational Studies in Epidemiology guidelines (5) .
Results
Study population. The search strategy retrieved 1,056 title abstracts for review. Of these 1,056 title abstracts, 257 full-text articles were retrieved and reviewed in detail (Fig. 1) .
Data for RNE after transcatheter closure and medical therapy were derived from 39 studies with 8,185 patients and 19 studies with 2,142 patients, respectively (6 -53) . Of these, 10 studies with 1,886 patients reported comparison of the 2 treatment modalities and were included for pooled comparative analysis (10, 14, 18, 20, 22, 23, 31, 37, 41, 42) . The distribution of patients in different study groups, along with their baseline characteristics, is demonstrated in Table 1 . Because there are no validated scales for assessment of quality of prospective case series, we assessed the quality on the basis of selection characteristics, ascertainment of outcome, and loss to follow-up. For comparative studies, comparability of cohorts was assessed on the basis of differences in baseline characteristics. Due to the inherent differences in the selection as well as baseline characteristics of these cohorts, we refrained from making firm conclusions on the basis of the pooled estimates derived from these comparative studies. The individual components of each of these quality parameters are demonstrated in Online Table 1 . Although administration of antiplatelet and/or anticoagulant therapy was observed to be a common practice after device closure, the regimen and the dosage varied considerably across the studies (Online Table 2 ). Low-dose aspirin with or without clopidogrel was the most common regimen used for thromboprophylaxis in the immediate postclosure period. RNE. Figure 2 demonstrates the pooled incidence of RNE among the transcatheter PFO closure and the medical therapy arms. The pooled incidence of RNE/100 PY among the transcatheter closure was estimated as 0.76 (95% CI: 0.48 to 1.05) events as compared with 4.39 (95% CI: 3.20 to 5.59) events in the medical therapy arm. With comparative studies, we calculated that there was a significantly reduced number of RNE among patients undergoing transcatheter closure as compared with those managed medically (RR: 0.25 [95% CI: 0.11 to 0.58]) (Fig. 2B) . Figure 3 demonstrates the comparison of RNE among the patients managed medically with anticoagulants versus antiplatelet medications. The incidence of RNE/100 PY in the antiplatelet arm was estimated as 4.2 (95% CI: 2.9 to 5.4) events as compared with 2.2 (95% CI: 1.1 to 3.4) events observed among patients receiving anticoagulation. Pooled analysis of the comparative studies yielded significantly lower risk of RNE among patients receiving anticoagulation as compared with those receiving antiplatelet medications (RR: 0.58 [95% CI: 0.41 to 0.82]). Device-related complications. Table 2 demonstrates the complications encountered in the post-procedural and follow-up period in the 2 study arms. The composite complication rate/100 PY in the transcatheter closure and the medical management arm was estimated as 4.1 (95% CI: 3.2 to 5.0) events and 0.4 (95% CI: 0 to 0.9) events, respectively. Transcatheter closures have been associated with a high rate of procedural success (failure rate: 0.01%). The reintervention rate in the follow-up period was esti- mated as 0.9% (95% CI: 0.2 to 1.6). The most frequent complication after transcatheter closure was reported to be atrial arrhythmias (incidence: 3.9% [95% CI: 2.7 to 6.1]). The incidence of device-related thrombosis was estimated as 0.6% (95% CI: 0.3 to 0.9). The proportion of patients with complications requiring surgical intervention was estimated as 0.3% (95% CI: 0.1 to 0.5). The rate of bleeding complications in the transcatheter closure arm was estimated as 1.7% (95% CI: 1.1 to 2.4). In comparison, the rate of bleeding complications in the medical therapy arm was estimated as 1.1% (95% CI: 0 to 2.5).
To determine the impact of improvement of procedural technique and device design, we analyzed the complication rate in the early period (2001 to 2005) and the late period (2006 to 2011) separately. Although there was a trend toward a reduction in the complication rate from the early period to the late period in both study groups, this difference was not statistically significant (p Ͼ 0.05 for both compar- isons). In the transcatheter closure arm, there was a small nonsignificant reduction in the incidence of perforation, device-related thrombosis, air embolism, bleeding complications, mortality, and residual shunting in the late period compared with the early period. In the medical therapy arm, there was a trend toward reduction in bleeding complications as well as mortality in the late period compared with the early period. Table 3 demonstrates the rates of RNE and major complications across the most common devices used in the included studies. Amplatzer (AGA Medical Corporation, Golden Valley, Minnesota) was the most common device used (38.5%), followed by the CardioSEAL (NMT Medical, Boston, Massachusetts) device (18.6%). The rates of RNE ranged from 0.1 to 1.7 events/100 PY across the various device types. Atrial arrhythmias were most frequently encountered with CardioSEAL (10.2/100 PY) and Starflex (NMT Medical) devices (9.0/100 PY) and least commonly with Amplatzer and Helex (Gore Medical, Flagstaff, Arizona) devices. Among all the devices used, device-related thrombosis was most commonly encountered with the Starflex (3.3/100 PY) and the PFO Star device (2.8/100 PY). Helex devices seemed to have the highest rates of medium-to long-term (14.8%) residual shunting and a slightly higher risk of device embolization or malposition (1.4/100 PY) as compared with other device types.
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PFO morphology. In the transcatheter closure arm, the incidence of RNE/100 PY among patients with PFO alone versus those with PFO and ASA was estimated as 0.3 (95% CI: 0.1 to 0.6) events and 0.4 (95% CI: 0.1 to 1.0) events, respectively. In the medical management arm, the respective incidence of RNE/100 PY among patients with PFO alone and PFO and ASA was estimated as 2.4 (95% CI: 0.9 to 4.0) events and 6.2 (95% CI: 2.8 to 9.6) events. In the transcatheter closure arm, there was no significant difference observed in RNE between the 2 morphological groups (RD: 0 [95% CI: Ϫ0.01 to 0.01]). However, in the medical management arm, there was significantly increased RNE observed in patients with PFO and ASA as compared with patients with PFO alone (RD: 0.03 [95% CI: 0.01 to 0.05]) (Fig. 4) . Figure 5 demonstrates the effect of increasing proportion of a large pre-treatment shunt upon incidence of RNE in both study arms. With an increasing proportion of patients with large shunts, a significant increase was lacking in the rate of RNE after transcatheter PFO closure. Although there was no apparent trend toward increasing RNE with increasing proportion of patients with large shunts in the medical arm, the rate of RNE in the medical arm was significantly higher than the transcatheter arm in corresponding shunt categories. Effect of age. Across the published data, studies used different cutoffs for defining "old" versus "young" popula- Due to significant paucity of articles studying the effect of thrombophilia on the optimal management strategy for stroke prevention due to PTE Table 2 ). This reduced to an estimated rate of 12.5% (95% CI: 9.6 to 15.5) in the first year of follow-up. On long-term follow-up beyond 1 year, this rate further dropped down to 6.3% (95% CI: 0.1 to 18.2) ( Table 2 ]. Figure 6 demonstrates the relationship between RNE and residual shunting reported in the respective studies. There was no particular trend noted in the incidence of RNE with increasing residual shunting reported during the follow-up period across the analyzed studies. In addition, we observed that the presence of residual shunting did not predispose individuals to increased risk of RNE in the follow-up period. Among the patients with RNE, the odds of having a residual shunt were significantly lower as compared with the odds of not having a residual shunt. This implies that the cause of RNE in the follow-up period in most individuals might be actually unrelated to the PFO and its closure. Meta-regression analysis. Due to significant differences in the baseline characteristics of the included studies, a significant limitation exists in terms of interpretation of pooled effect estimates derived from these studies. Metaregression analysis was performed to ascertain empirical differences in RNE rates between the 2 groups, after adjustment for mean age, proportion of men in the study, and the proportion of patients with ASA. Interaction of the choice of strategy with each of these variables was tested individually and collectively, and was not statistically significant. After adjustment of these variables, there was a significant reduction of RNE in patients undergoing transcatheter closure by 3.5 (95% CI: 2.1 to 5.0) events/100 PY, in comparison with those managed medically (p Ͻ 0.001). Publication bias. The effects of publication bias on the meta-analysis of RNE in the 2 study arms are demonstrated in Online Figures 1 and 2 . We observed that there was no significant publication bias in the meta-analysis of RNE after transcatheter closure (p ϭ 0.8). However, the metaanalysis of RNE after medical therapy has significant publication bias (p ϭ 0.015), which persisted even after restricting the studies to include only those with n Ͼ 100. With the "fill and trim" method, the corrected effect estimate for RNE after medical therapy was estimated as 5.0 (95% CI: 3.6 to 6.9) events/100 PY (4). 
Discussion
Our meta-analysis seeks to understand the available evidence for transcatheter closure in prevention of recurrent PTE in patients with cryptogenic stroke or TIA, compared with medical management. The incidence of RNE/100 PY was estimated at 0.8 and 5.0 events in the transcatheter closure arm and medical therapy arm, respectively. Metaanalysis of the small number of comparative studies and the meta-regression analysis indicated that there might be a significant benefit in reduction of RNE with transcatheter closure in comparison with the medical therapy alone. Moreover, in the medical management arm, the risk of RNE was significantly lower with anticoagulation therapy compared with antiplatelet therapy.
The device-related complication rate was estimated as 4.1 complications/100 PY in the closure arm. The most common complication after transcatheter closure was development of atrial arrhythmias. The incidence of residual shunt was 12.5% in the first year of follow-up, which reduced to 6.3% on long-term follow-up beyond 1 year. We did not observe an increase in the risk of RNE during the follow-up period among individuals with persistent residual shunt in the post-procedure period, as compared with those without residual shunt. Moreover, among individuals with RNE, the odds of lacking a residual shunt were significantly higher than having one. This might suggest that a non-PFO-related cause is often responsible for recurrent thromboembolic events in individuals who have undergone a transcatheter PFO closure in the past. In patients with small residual shunts noted on medium-term follow-up after closure, a trend toward complete elimination of the shunt has been observed, justifying a conservative attitude in management of residual shunt, although there are reports of using a second device for management of moderate to large residual shunts (60) . Age and transcatheter closure. A strong association has been demonstrated between cryptogenic stroke and PFO in patients Ͻ55 years of age (61) . Due to the greater number of stroke causes in older patients, the relationship between cryptogenic stroke and PFO is harder to establish in these patients (62) . We observed a significantly higher rate of RNE in the older age group managed medically as compared with the younger age group. However, the rate of RNE was similar between the older and younger age groups undergoing transcatheter closure. This implies that older individuals with cryptogenic stroke/TIA might derive a benefit of lower rate of RNE by undergoing transcatheter PFO closure. Morphology and transcatheter closure. There have been several morphological attributes of PFO-such as tunnel length, size, presence or absence of multiple fenestrations, relative thickness of the septal components, ASA, and septal hypermobility-that have influenced the choice of devices across the published data. The prevalence of ASA in the general population has been estimated to range between 1% in autopsy studies to 2.2% in the echocardiography-based studies (63) . The presence of PFO with ASA has been shown to increase the risk of RNE (51) . Our metaanalysis demonstrated an increased rate of RNE among individuals with PFO and ASA undergoing medical management in comparison with patients with PFO alone. However, in the transcatheter arm, there was no significant difference in the rate of RNE between the 2 subgroups, indicating a beneficial effect of transcatheter closure in preventing recurrent thromboembolic events in PFO significantly increases the risk of recurrent thromboembolic episodes (19, 64) . Our meta-analysis demonstrated that there was no significant difference in the rate of RNE between patients with or without thrombophilia undergoing transcatheter closure. This might imply that the transcatheter PFO closure helps alleviate the risk of RNE among patients with thrombophilia to the levels encountered by those without any hypercoagulable state. Clinical perspective. Despite over 15,000 closure procedures reported in the published data, controversy still persists with regard to indication for transcatheter PFO closure over medical therapy. There are several ongoing randomized trials comparing the efficacy of transcatheter PFO closure with medical therapy in prevention of recurrent thromboembolic events; the CLOSURE 1 trial is the only completed trial (2) . Why do we find suggestion of benefit with observational studies but were not able to prove that in the CLOSURE 1 trial? There are several interesting points about the trial that are worth considering. One, the trial included patients with stroke and TIA. Two, many recurrent strokes reported in the trial were device-related. Three, the cause of recurrent stroke was not PTE in most patients. The trial suggested that all patients with neurological symptoms and concomitant PFO should not undergo transcatheter PFO closure. However, our meta-analysis suggests that real-world selection of high-risk patients where PFO was more likely to be the cause of the stroke is likely to be a more beneficial strategy in successful prevention of RNE after transcatheter closure. How would we accomplish this? Meticulous attention to patient selection with detailed history and work-up to eliminate other etiologies of stroke and maximizing the likelihood of PTE as an etiology for stroke by detailed evaluation of PFO morphology and thrombophilia can help identify patients at risk of RNE secondary to PTE through a PFO. Furthermore, our meta-analysis clearly suggests that, among patients destined to medical management, use of anticoagulant therapy is far superior to antiplatelet therapy alone for prevention of RNE. Barring definite contraindication to warfarin use, anticoagulant therapy should be strongly preferred for stroke prevention in medically managed patients who present with PTE. Study limitations. The choice of medical therapy versus transcatheter closure is usually dependent on the preference of the patient for a particular therapy, allowing a self-selection bias. Systematic pooling of different observational studies with different baseline characteristics might induce some imprecision in the results due to heterogeneity. Several studies included in the meta-analysis have small numbers or have short follow-up periods. Due to relative rarity of RNE after transcatheter closure, recurrent events are more likely to be observed in larger study samples with a longer follow-up period.
The present meta-analysis is limited by the possibility of a strong selection bias, which forms at least 1 rationale for conducting the study. Several studies might report erroneous estimates due to inclusion of patients who have "undiagnosed yet unrelated" source of thromboembolism rather than PTE secondary to PFO (Fig. 7) . There exists a chance that the results might be fundamentally skewed in a nonrandom fashion when comparing one population (transcatheter) to another (medical therapy). Despite these limitations, our meta-analysis seeks to clarify an extensive and confusing published data by systematic organization and aggregation of available information. Conclusive data from the ongoing randomized control trials would help clarify this question in a more definitive manner.
Conclusions
Accepting the limitations of this comparative metaanalysis of observational studies, we observed that transcatheter PFO closure was associated with an 84% reduction in the rate of RNE compared with medical management (0.8 events/100 PY compared with 5.0 events/100 PY). Comparison of the anticoagulation and antiplatelet therapy subgroups of the medical arm yielded a significantly lower risk of RNE in patients treated with anticoagulants. Device-related complications were encountered at the rate of 4.1 events/100 PY, with atrial arrhythmias being the most frequent complication. The risk of recurrent thromboembolism did not seem to be related to presence of residual shunting in the follow-up period. Significant benefit of transcatheter PFO closure was apparent in elderly patients, patients with concomitant ASA, and patients with thrombophilia. 
